Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03630120
Title Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

thyroid gland cancer

Therapies

Lenvatinib + Sorafenib

Cabozantinib + Vandetanib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.